

Index

A

Absorption, ADME 153
Accuracy 72
AcpS inhibitors 199
Activity 73
–cellular 185
–distribution 73
–SAR patterns 22
–verification, resynthesized sample 18
ADME 144, 153, 169, 175, 192
–in vitro 187
Adverse drug reactions 167
AGP, equilibrium dialysis assays 186
Aldehyde oxidase 155
Alzheimer’s disease 206
Ames assay 165, 166
Amyloid β -peptide 205
Arachidonic acid 192
Array synthesis 181
Artifact 73
Assay 73
Assay control, negative 73
–positive 74
Assay design/development 25, 29, 191
Assay format 74
Assay validation 74
Autoimmune diseases 197
Automation 25, 27, 53, 74

B

BACE-1 inhibitors 195
Background 73

Base buffer 32
Batch 74
BBB PAMPA 188
Bead-based assays 39
Buffer components, optimization 32

C

Camptothecin 208
Carcinogens, genotoxic 165
Cathepsin D 206
Cations, monovalent/divalent 32
CCR1 antagonists 207
CCR4 antagonists 192
CCR5 antagonists 203
CDC25 phosphatases 109
CDK2 inhibitors 204
Cell density 33
Cellular activity 185
CGRP antagonists 196
Chalcones 101
Chemical biology screening 15
Chemical genetics screening 15
Chemical shift perturbation 130
Chemoinformatics 10
Chemokine receptors 201, 203
CHK-1 inhibitors 208
Chlamydia pneumoniae 108
Chloroquine-resistance reversal agents 101
Clearance 152
Closed loop, hit to lead 19
Clustering, series formation 179
Compound collection/library 75

Compound quality filters 17
Computational models 167
Concentration response 75
Counter-screen 75
cPLA₂α inhibitors 192
CXCR2 antagonists 201, 202
CYP inhibition, mechanism-based 163
Cystic fibrosis 111
Cytochrome P450 144

D

Data, knowledge/probability 143
–analysis, tools 189
–management 25, 61, 63
Database creation 91
–filtering 92
Decision making 168
Deliverables 54
Detergents 32
Dimethylarginine dimethylaminohydrolase 111
Distribution 150
Diversity-oriented synthesis (DOS) 7
DMSO 50
–tolerance 32
DNA, damage/genetic toxicity 166
DNA primase, inhibitors 108
Docking 85
Dopamine 96
–re-uptake inhibitors *xi*
Doxorubicin 208
DPP-IV inhibitors 112, 205
Drug design, structure-based 109
Drug discovery 125
–druggability/developability 5, 166
–efficiency 141
–screening 16
–triage 141
Drug–drug interactions 167

E

EAAT inhibitors, selective *xi*
Effective concentration 50 (EC₅₀) 75
Efficacy 75
Enrichment factor 89
Enzyme ‘stabilizers’ 32
Enzymology 179

Erectile dysfunction 200
Excretion 150
Experimental data, pharmacokinetics 150
–potency 146
–safety 159

F

False negatives 14, 76
False positives, stochastic/nonstochastic 13, 76
Flavin-containing monooxygenases (FMO) 155
Fluidics 66
Fluorescence polarization (FP) 38
Fragment-based drug discovery 125, 126
Fragment-based virtual screening 112
Fragment screening 8, 150
Functional groups to avoid 17

G

GAL4 reporter assay 43
Genetic toxicity 166
Ginkgolides, GABA modulators 101
Glutamate receptors, metabotropic 206
–mGluR1 inhibitors 206
Glutathione adducts 166
glutathione transferases (GST) 155
GPCRs 9, 12, 44, 68, 188, 192
–CC chemokine family 192

H

HCV NS5B polymerase inhibitors 195
Heme oxygenase 108
hERG 47, 101, 163, 187
–inhibition 188
High content screening (HCS) assay 76
High throughput screening (HTS) 1, 6, 25, 77, 85, 142
High-order pattern recognition 10
Hit to lead 1, 125
–closed loop 19
–confirmation 35
–multiple vs single chemical series 20
–optimization, exit criteria 22
–rate 33, 77
–threshold 77

Hit triage *xi*, 12, 19, 141, 142
–information collection 171
–philosophy 142
Hits 76, 141
–biophysical characterization 179
–characterization 179
–drug-like 152
–enzymology 179
–lead-like 152
–selection 58
–sources 142
HIV 203
HIV integrase 111
HIV reverse transcriptase 111
Homogeneous time resolved fluorescence
(HTRF) 39
Homology modeling 9
HSA, equilibrium dialysis assays 186
HTS 1, 6, 25, 85
–assay development/validation 33
–campaign 35
–conducting an 27
–defined mechanism screen 11
–false positives 12
–in academics 71
–library sign 11
–phases 31
–process 28
–success, optimistic view 60
–pessimistic view 59
–true positive hit rates 12
Hybrid workflows 85, 109

I

IKK β inhibitors 197
IL-2 207
IL-8 201
Incubation 33
Information, collecting/analyzing 141
Insulin secretion 97, 205
Insulin sensitizers 43
Intellectual property 191
Interleukin-2 207
Interleukin-8 201
Ion channels 47, 180
Isoforms 166
ITK inhibitors 207

K

Kinases 41, 70

L

Lead, definition 77, 178
–discovery 85
–high quality 175
–identification 85
–profile 178
Ligand-based virtual screening 85, 93
Ligand binding, transferred NMR 132
Ligand efficiency 150
Ligand profile screening 165
5-Lipoxygenase inhibitors 95
Liquid handler (liquid handling machine)
78
Liquid handling steps 33
Logistics 36, 52

M

Mapping, non-linear 189
MCH1 receptor antagonists 194
Mechanism-based inactivation (MBI) 167
Metabolism 150, 187
Metabolite identification 187
Metal chelators 32
Microplate 78
–standards 78
Miniaturization 66
Module 78
Monoamine inhibition *xi*
monoamine oxidases (MAO) 155
Multiple sclerosis 207
Multivariate data analysis (MVA) 189

N

Neisseria meningitidis 108
Neuropeptide, vasodilator 196
Neurotransmitters *xi*
NLP searchable form 114
NMR 125
NOEs, intramolecular 134
Noise 78
Nonnucleoside reverse transcriptase
inhibitors (NNRTI) 111
Noradrenaline re-uptake inhibitors *xi*

Nuclear receptors (NRs) 43
 μ -Opioid receptor modulators 199

P

P2X₇ inhibitors 204
Parallel artificial membrane permeability assays (PAMPA) 159
Parallel optimization 181
–parameters 85
Parameters, parallel optimization 85
Patentability assessment 180
Pattern recognition 1
PDE1/PDE5 inhibitors 200, 97
Permeability/absorption 153
pH optimization 32
Pharmacokinetic data, collection 141
Pharmacokinetics 143, 188
Pharmacophore-based methods 98, 180, 190
Phenotypic assays 48
Phenotypic screening 6
PK 175
pK_a 186
PKC θ inhibitors 198
Plate format 51, 79
Plate map 79
Platforms 29
Polymerase inhibitors 195
Positron emission tomography (PET) *xi*
Potency 184
PPAR agonists 43
Precision 79
Preformulation 21
Primary screen 79
Profiling, hit to lead 20
Proteases 42
Protein–protein interactions 48
Pseudomonas aeruginosa 111

Q

Quality control 28, 31, 79

R

RAR β 2 receptor agonists 195
Reactive metabolite formation 163
Reagent concentrations/volumes 33

Reducing agents 32
Reproducibility 33, 80
Re-uptake inhibitors, mixed *xi*
Rheumatoid arthritis 207
RNA polymerase, RNA-dependent 195
Robotic assay adaptation/validation 34
Robustness 80
ROCS 99

S

β -Secretase 205
Safety 141
SAR, ILOEs 125
SAR/SPR 178
Saturation transfer difference (STD) 134
Scoring 85
Screen 80
–validation 80
Screening, goal 15
–sample management 30
–smarter approaches 69
Secondary screen 81
Selectivity 184
–assay 81
Series 141
Serotonin re-uptake inhibitors *xi*
Similarity search 181
Singletons 35, 179
Sirtuin-2 histone deacetylase inhibitors 102
Solubility 155
Stability 33
Staff development 64
Statistics 25, 55, 58
Storage conditions 50
Structure-based virtual screening (SBVS) 102
Structure organization 28
Structure verification 18
Substrate/ligand/inhibitor specificity 33
Substructure search 181
Surface plasmon resonance (SPR) 8
Surflex-Sim 99
Synthetic targets 190

T

T cell signaling 198
Target 81

Targeted library 81
Text-mining, virtual screening 113
Transporters *xi*
Triage *xi*, 12, 19, 141, 142
Tricyclic antidepressants (TCAs),
toxicology 187

V

Virtual screening (VS) 85
–benchmarking 85, 89

–fragment-based 85
–ligand-based 85
–receptor structure-based
(SBVS) 102
–strategy 85, 116
–structure-based (SBVS) 102
–text-mining 113

Z

Zhang factor 55